PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
about
Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infectionTreatment for hepatitis C virus-associated cryoglobulinaemic vasculitisThe place of immunotherapy in the management of HCV-induced vasculitis: an updateDiagnosis, management, and treatment of hepatitis C: an updateHepatitis C virus-related lymphoproliferative disorders: an overview.Central nervous system vasculitis and polyneuropathy as first manifestations of hepatitis CHepatitis C virus as a multifaceted disease: a simple and updated approach for extrahepatic manifestations of hepatitis C virus infectionLife-Threatening Cryoglobulinemic Patients With Hepatitis C: Clinical Description and Outcome of 279 Patients.Improving anti-hepatitis C virus therapy.Management of chronic hepatitis C: consensus guidelines.Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experience.An approach to the patient with retiform purpura.Hepatitis C Virus-related Mixed Cryoglobulinemia: Pathogenesis, Clinica Manifestations, and New TherapiesManagement of rheumatic disease with comorbid HBV or HCV infection.Hepatitis C virus infection and mixed cryoglobulinemiaAutoimmune manifestations in viral hepatitis.Diagnostics and treatment of cryoglobulinaemia: it takes two to tango.Membranoproliferative glomerulonephritis, type II cryoglobulinemia and triple therapy for hepatitis C: a case series and review of the literature.Hepatotropic viral infection associated systemic vasculitides-hepatitis B virus associated polyarteritis nodosa and hepatitis C virus associated cryoglobulinemic vasculitis.Resolution of neurological deficits secondary to spontaneous intracranial haemorrhage and posterior reversible encephalopathy syndrome (PRES) in a patient with hepatitis C-associated cryoglobulinaemia: a role for plasmapheresis.Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study.A retrospective analysis of treatment outcomes in patients with hepatitis C related systemic vasculitis receiving intravenous methylprednisolone and cyclophosphamide.Severe hepatitis C virus-related cryoglobulinaemic sensory-motor polyneuropathy treated with pegylated interferon-a2b and ribavirin: clinical, laboratory and neurophysiological study.Hepatitis C-related cryoglobulinemic neuropathy: potential role of oxcarbazepine for pain control.Hepatitis C: the complications of immune dysfunction.The association of cryoglobulinaemia with sustained virological response in patients with chronic hepatitis C.Relationship between cryoglobulinemia-associated nephritis and HCV infection.Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We at the End of the Road?Expression of biomarkers of interferon type I in patients suffering from chronic diseasesA randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis
P2860
Q24187162-9233B90C-9D57-4C68-9A20-09C2CDDD2287Q24188154-B4919D7A-E109-47A4-8FD8-1E1CAD447E8EQ27015124-EC13567F-19F9-45DD-BB4F-CFBE520CAAC6Q29619682-C15B84A4-11FB-4E0F-8F89-BEA05BF9B028Q34098553-1201978A-D1A0-4F11-9DB7-9C7026B03D73Q35670470-2A97E3FC-4E62-4B72-BD21-A39E62C5441BQ35731058-36CF4E1D-9864-44CC-BBA2-AF22780D193FQ36008973-7F7077A6-B535-4563-8854-575ADFD3227DQ36569749-D634FCC0-D0B4-4452-A468-741252B818C5Q36849347-64FA9EF6-0D90-4325-A7A4-879AC6C86B45Q37742383-AD5B90D6-4EB2-4803-B440-BC7DF43C87A0Q37853593-96CF0A66-4563-4248-A9DE-1928CB6BACF4Q37940987-6112E65B-64E7-4BD5-91C8-94DB7C0BE218Q38008173-B9E4C1C8-D720-40CE-BD97-A3B8A603322FQ38030533-AD4E7641-1B13-4D59-8B67-DA1926A31615Q38046450-A622FDD3-9AAE-4A2D-96D8-E9FD50E28A55Q38143718-AFFA913A-BBBC-4BE0-B7A8-78168D54A141Q38196327-7E5E38A8-BBAC-4A20-9CF1-D0E8BC037D38Q38371537-12B24CBA-AA73-4650-BB3A-82BB16D779FCQ41877545-3D721B21-31FF-4E60-ADDD-BADD41837945Q42180401-2C1DEB55-8FDF-4E18-AE0A-3EC6DA932BA2Q43000401-1550630A-6CAE-40BC-BE75-DED854685A5FQ45406307-2EFCD05E-0F81-4BA3-B420-92BD16FC91D1Q47548875-A05E3787-2D3D-445F-93B1-85311B0D28FAQ47580213-2BC57FB1-A53E-4B10-977E-C6EB4C5B6927Q50558415-FD47B342-29D6-4897-9382-B90411EFC12FQ50568204-F789D88C-5636-4152-835F-BED97E4B8CACQ54216578-7D1EE0C9-ABDA-4F8C-A5E2-E261E384D061Q57632335-3888CEF2-8FC3-4A6B-A461-F20522FA9ACFQ58377805-4F1E3AEF-5E82-4838-86AC-BE5008471D19
P2860
PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
PEGylated interferon alfa-2b a ...... s-related systemic vasculitis.
@en
PEGylated interferon alfa-2b a ...... s-related systemic vasculitis.
@nl
type
label
PEGylated interferon alfa-2b a ...... s-related systemic vasculitis.
@en
PEGylated interferon alfa-2b a ...... s-related systemic vasculitis.
@nl
prefLabel
PEGylated interferon alfa-2b a ...... s-related systemic vasculitis.
@en
PEGylated interferon alfa-2b a ...... s-related systemic vasculitis.
@nl
P2093
P356
P1476
PEGylated interferon alfa-2b a ...... s-related systemic vasculitis.
@en
P2093
Damien Sene
David Saadoun
Nicolas Limal
Olivier Lidove
P304
P356
10.1002/ART.20958
P577
2005-03-01T00:00:00Z